相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
A. L. Wong et al.
ANNALS OF ONCOLOGY (2015)
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2 '-O-(2-Methoxyethyl) Modifications
Rosie Z. Yu et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Prognostic value of circulating cytokines on overall survival and disease-free survival in cancer patients
Laura Visconti et al.
BIOMARKERS IN MEDICINE (2014)
Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
Ho-June Lee et al.
CANCER CELL (2014)
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
Johanna C. Bendell et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Systemic Administration of a Cyclic Signal Transducer and Activator of Transcription 3 (STAT3) Decoy Oligonucleotide Inhibits Tumor Growth without Inducing Toxicological Effects
Malabika Sen et al.
MOLECULAR MEDICINE (2014)
Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model
Toshi Murakami et al.
LUNG CANCER (2014)
Targeting APOC3 in the Familial Chylomicronemia Syndrome
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples
Frency Varghese et al.
PLOS ONE (2014)
STAT inhibitors for cancer therapy
Muhammad Furqan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2013)
Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys
Sebastien A. Burel et al.
NUCLEIC ACID THERAPEUTICS (2013)
Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype
Charlie Mantel et al.
BLOOD (2012)
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
Thurman M. Wheeler et al.
NATURE (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues-a comparative study of oligonucleotide length, design and chemistry
Sue Murray et al.
NUCLEIC ACIDS RESEARCH (2012)
STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
Brendan D. Looyenga et al.
PLOS ONE (2012)
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane
Jonathan E. Zuckerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
Malabika Sen et al.
CANCER DISCOVERY (2012)
STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma
Anna Scuto et al.
CANCER RESEARCH (2011)
A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
David S. Hong et al.
CLINICAL CANCER RESEARCH (2011)
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
Fred Saad et al.
CLINICAL CANCER RESEARCH (2011)
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
Davide Torti et al.
EMBO MOLECULAR MEDICINE (2011)
JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling
Lanxi Song et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
Erich Koller et al.
NUCLEIC ACIDS RESEARCH (2011)
Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
Denis C. Talbot et al.
CLINICAL CANCER RESEARCH (2010)
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
C. A. Stein et al.
NUCLEIC ACIDS RESEARCH (2010)
Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship
Hyunsoo Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat et al.
CANCER CELL (2009)
Short Antisense Oligonucleotides with Novel 2′-4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
Punit P. Seth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Imatinib and beyond-exploring the full potential of targeted therapy for CML
Alfonso Quintas-Cardama et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Daniel J. Gough et al.
SCIENCE (2009)
Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expression
Emily C. Brantley et al.
CLINICAL CANCER RESEARCH (2008)
Translating insights from the cancer genome into clinical practice
Lynda Chin et al.
NATURE (2008)
Nonviral delivery of synthetic siRNAs in vivo
Saghir Akhtar et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome
Yoshiyuki Minegishi et al.
NATURE (2007)
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
David B. Rozema et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment II
C. R. Taylor et al.
HISTOPATHOLOGY (2006)
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors
Meili Zhang et al.
BLOOD (2006)
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
R Chiarle et al.
NATURE MEDICINE (2005)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-α, in combination with cisplatin and genicitabine in patients with advanced non-small cell lung
MA Villalona-Calero et al.
CLINICAL CANCER RESEARCH (2004)
Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines
D DeArmond et al.
ONCOGENE (2003)
A functional role of Stat3 in in vivo megakaryopoiesis
K Kirito et al.
BLOOD (2002)
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
A Zamo et al.
ONCOGENE (2002)
Rac1 mediates STAT3 activation by autocrine IL-6
TR Faruqi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
